Alvotech and Teva Celebrate New SELARSDI Approval
Alvotech and Teva Pharmaceuticals have exciting news for patients with immune-mediated conditions. The U.S. FDA has green-lighted SELARSDI (ustekinumab-aekn) in a new intravenous infusion format, extending its use for adults suffering from Crohn’s disease and ulcerative colitis. This latest development opens the door for SELARSDI to offer more comprehensive treatment options synchronized with its reference product, Stelara.
Significant Milestones in SELARSDI's Journey
This new approval comes after the FDA's nod to SELARSDI in earlier presentations. The previously approved formats include a 45 mg/0.5 mL and a 90 mg/mL solution, both designed for subcutaneous injection. Moving forward, the introduction of the 130 mg/26 mL single-dose vial signifies a pivotal moment for Alvotech's strategy, intending to enhance accessibility for patients dealing with severe forms of these diseases.
Impact on Patient Care
Robert Wessman, Chairman and CEO of Alvotech, expressed optimism about the latest approval. He stated, "We welcome this step which is fully in line with our plan to align SELARSDI's label with the indications of the reference product, prior to our launch next year.” The company anticipates a U.S. launch in the first quarter of 2025, a timeline that promises hope for many patients eagerly awaiting access to treatment.
A Commitment to Accessibility
Thomas Rainey, Senior Vice President of U.S. Biosimilars at Teva, echoed this sentiment. He remarked on the milestone achieved with the expanded indications and highlighted Teva's ongoing dedication to making biosimilars accessible to patients across the U.S. This collaboration between Teva and Alvotech aims not only to improve patient outcomes but also to strengthen the biosimilar market in the U.S.
Expanding the Pipeline with SELARSDI
SELARSDI is indicative of Alvotech's broader commitment to develop biosimilars aimed at treating various autoimmune diseases. Utilized for conditions like plaque psoriasis and psoriatic arthritis, SELARSDI targets two key cytokines—IL-12 and IL-23—known to play essential roles in immune responses. By producing SELARSDI within a similar continuous perfusion process as Stelara, Alvotech aims to uphold high standards of quality and efficacy in their biosimilar offerings.
Progressing Through Strategic Partnerships
Since establishing a strategic partnership with Teva in 2020, Alvotech has seen significant growth within its biosimilar product pipeline. This collaboration has resulted in multiple FDA approvals, including SELARSDI and SIMLANDI (adalimumab-ryvk), which further showcase their joint commitment to increasing global access to life-changing medications.
Beyond SELARSDI: The Vision for the Future
Alvotech is not merely stopping with SELARSDI; its pipeline continues to grow robustly. With a focus on autoimmune disorders, eye conditions, osteoporosis, and even cancer, the company showcases an ambitious roadmap towards improving patient care globally. The strategic partnerships with companies like Teva enable them to navigate the complexities of market entry and commercial distribution effectively.
Teva's Legacy and Future Endeavors
Teva, a global pharmaceutical leader, has over a century of experience in providing quality medicines. Their commitment to enhancing health outcomes through rigorous research and the introduction of innovative treatments remains unfaltering. With 37,000 employees driving research and development across various markets, Teva invigorates its operations by expanding the availability of biosimilars like SELARSDI.
Frequently Asked Questions
What is SELARSDI used for?
SELARSDI is used to treat adults with conditions like Crohn’s disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis.
When will SELARSDI be available in the U.S.?
The U.S. launch of SELARSDI is anticipated in the first quarter of 2025.
Which diseases does SELARSDI target?
SELARSDI primarily targets immune-mediated diseases, particularly Crohn's disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis.
What is the significance of this FDA approval?
This FDA approval allows SELARSDI to be used in more treatment modalities, enhancing patient access to care.
How do Alvotech and Teva collaborate?
Alvotech focuses on the development and manufacturing of biosimilars while Teva drives the commercialization efforts in the U.S., ensuring broad access to therapies.
